Is Prelude Therapeutics Inc (PRLD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.9% / 30% | 65.8% / 30% | 0.0% / 30% | 179.16% / 5% | ✗ NOT HALAL |
| DJIM | 8.9% / 33% | 65.8% / 33% | 0.0% / 33% | 179.16% / 5% | ✗ NOT HALAL |
| MSCI | 10.3% / 33% | 76.1% / 33% | 0.0% / 33% | 179.16% / 5% | ✗ NOT HALAL |
| S&P | 8.9% / 33% | 65.8% / 33% | 0.0% / 33% | 179.16% / 5% | ✗ NOT HALAL |
| FTSE | 10.3% / 33% | 76.1% / 33% | 0.0% / 50% | 179.16% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -284.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -99.5% | |
| Return on Assets (ROA) | -40.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$56M |
| Free Cash Flow | -$56M |
| Total Debt | $18M |
| Debt-to-Equity | 25.9 |
| Current Ratio | 2.0 |
| Total Assets | $141M |
Price & Trading
| Last Close | $3.24 |
| 50-Day MA | $2.62 |
| 200-Day MA | $1.69 |
| Avg Volume | 391K |
| Beta | 0.9 |
|
52-Week Range
$0.61
| |
About Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Prelude Therapeutics Inc (PRLD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Prelude Therapeutics Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Prelude Therapeutics Inc's debt ratio?
Prelude Therapeutics Inc's debt ratio is 8.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.3%.
What are Prelude Therapeutics Inc's key financial metrics?
Prelude Therapeutics Inc has a market capitalization of $192M, and revenue of $12M. Return on equity stands at -99.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.